Presented by Kenneth C. Anderson, MD, Dana-Farber Cancer Institute, Boston, Massachusetts.
J Natl Compr Canc Netw. 2016 May;14(5 Suppl):675-7. doi: 10.6004/jnccn.2016.0190.
The updated NCCN Guidelines for Multiple Myeloma feature several changes in the diagnosis and management of this disease. Criteria for treatment initiation have been broadened, new staging has been recommended, and new classes of agents and combinations are included as recommended treatment. Monoclonal antibodies are among the expanded therapeutic choices, along with a histone deacetylase inhibitor and third-generation proteosome inhibitor, and there is excitement about exploring new immune-based approaches.
美国国家综合癌症网络（NCCN）多发性骨髓瘤指南更新版对该病的诊断和治疗提出了一些改变。治疗起始标准已放宽，新的分期系统被推荐，新的药物类别和联合方案被纳入推荐治疗方案。扩展的治疗选择包括单克隆抗体，组蛋白去乙酰化酶抑制剂和第三代蛋白酶体抑制剂，人们对探索新的免疫治疗方法感到兴奋。
